Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

clarkhealthcommunications

- PMLiVE

GSK’s ViiV shares positive head-to-head results for two-drug HIV regimen Dovato

The phase 4 trial has been comparing Dovato against Gilead’s three-drug regimen, Biktarvy

- PMLiVE

Researchers develop AI model to identify breast cancer stages and progression

Up to 50% of ductal carcinoma in situ patients progress to a highly invasive stage of cancer

- PMLiVE

How good are you at filtering fact from fiction?

By Vicky Bramham

- PMLiVE

How patient engagement improves outcomes in chronic illness

By Chloe Patel

- PMLiVE

Generative AI, storytelling and patient inclusion: key publications trends in 2024

By Teal Brechtel and Jennifer Gillman

Amiculum

- PMLiVE

FDA approves Samsung Bioepis’ Soliris biosimilar Epysqli for rare blood disorders

Epysqli has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

- PMLiVE

MHRA approves first generic raltegravir medicines to treat HIV in adults and children

More than 91,000 people in England were diagnosed with HIV and accessing care in 2022

- PMLiVE

Paratek announces positive late-stage results for Nuzyra in bacterial pneumonia

The condition, caused by various bacteria, affects more than 900,000 people in the US every year

- PMLiVE

Q&A with Springer Nature’s Leslie Lansman

Ethical content sharing and the benefits of the CLA Pharmaceutical Licence

- PMLiVE

Missed Origins’ Webinar? Watch How Patient Experience Data is Changing Pharma!

We are thrilled to announce that the recording of our recent webinar, "Patient Data: From data to decisions, maximising the impact of patience experience data in pharma" is now available...

Origins – The Patient Focused Specialists

- PMLiVE

New report now available: Integrating ‘patient first’ into medicine development

A new report has just been published by Cuttsy+Cuttsy that collates all the current best thinking in the ‘patient first’ space, distilling it into a practical and actionable road map...

Cuttsy + Cuttsy

- PMLiVE

J&J’s Tecvayli recommended by NICE to treat relapsed and refractory multiple myeloma

Approximately 5,900 new cases of the blood cancer are diagnosed every year in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links